Zhan Chenyang, Bu Jun, Li Sheng, Huang Xiujin, Quan Zongjie
Department of General Surgery, Chengdu Second People's Hospital, Chengdu, China; School of Clinical Medicine, Chengdu Medical College, Chengdu, China.
Department of General Surgery, Chengdu Second People's Hospital, Chengdu, China.
J Gastrointest Surg. 2025 Feb;29(2):101898. doi: 10.1016/j.gassur.2024.101898. Epub 2024 Nov 26.
A decrease in skeletal muscle mass is frequently observed during the perioperative period in patients with gastric cancer (GC) and is strongly associated with postoperative complications and poor long-term survival outcomes. Relevant research indicates that a certain proportion of patients with GC experience skeletal muscle mass loss after surgery. Therefore, a systematic review and meta-analysis was conducted to assess postoperative skeletal muscle loss as a prognostic marker for clinical outcomes in patients with GC.
PubMed, Web of Science, and Embase were used to systematically screen and retrieve relevant studies according to strictly established inclusion and exclusion criteria. Further analysis of the effect of postoperative skeletal muscle loss on long-term survival metrics (including overall survival [OS], recurrence-free survival [RFS], disease-free survival [DFS], and disease-specific survival [DSS]) in patients with GC was performed.
RESULTS': From 10 studies and 11 related publications, more than 3764 patients with GC were identified. Severe postoperative skeletal muscle loss occurred in 25.7% of patients with GC and was significantly correlated with poorer OS (hazard ratio [HR], 2.27; 95% CI, 1.58-3.25; P <.00001), RFS (HR, 2.96; 95% CI, 1.47-5.97; P =.002), DFS (HR, 2.41; 95% CI, 1.17-4.97; P =.02), and DSS (HR, 4.12; 95% CI, 2.44-6.94; P <.00001). When postoperative skeletal muscle loss advanced to sarcopenia, patients had worse OS as well (HR, 2.22; 95% CI, 1.49-3.30; P <.0001).
Patients who undergo radical surgery for GC often experience skeletal muscle mass loss, and significant skeletal muscle mass loss is associated with poorer survival outcomes. Identifying patients with significant skeletal muscle mass loss during follow-up and promptly providing tailored interventions, such as nutritional and exercise support, are essential.
在胃癌(GC)患者围手术期,骨骼肌质量下降现象常见,且与术后并发症及长期生存不良结局密切相关。相关研究表明,一定比例的GC患者术后会出现骨骼肌质量丢失。因此,进行了一项系统评价和荟萃分析,以评估术后骨骼肌丢失作为GC患者临床结局的预后标志物。
根据严格制定的纳入和排除标准,使用PubMed、Web of Science和Embase系统筛选和检索相关研究。进一步分析了术后骨骼肌丢失对GC患者长期生存指标(包括总生存期[OS]、无复发生存期[RFS]、无病生存期[DFS]和疾病特异性生存期[DSS])的影响。
从10项研究和11篇相关出版物中,识别出3764例以上GC患者。25.7%的GC患者术后发生严重骨骼肌丢失,且与较差的OS(风险比[HR],2.27;95%置信区间[CI],1.58 - 3.25;P <.00001)、RFS(HR,2.96;95% CI,1.47 - 5.97;P =.002)、DFS(HR,2.41;95% CI,1.17 - 4.97;P =.02)和DSS(HR,4.12;95% CI,2.44 - 6.94;P <.00001)显著相关。当术后骨骼肌丢失发展为肌肉减少症时,患者的OS也更差(HR,2.22;95% CI,1.49 - 3.30;P <.0001)。
接受GC根治性手术的患者常出现骨骼肌质量丢失,显著的骨骼肌质量丢失与较差的生存结局相关。在随访期间识别出骨骼肌质量显著丢失的患者,并及时提供针对性干预措施,如营养和运动支持,至关重要。